Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275189 | 0.90 | TAAR1 (0.49) | TAAR1CYP2D6TSHRMTORADK | |
| SCHEMBL29044898 | 0.90 | TAAR1 (0.41) | TAAR1CYP2D6TSHRMTORADK | |
| SCHEMBL30515454 | 0.86 | TAAR1 (0.41) | TAAR1CYP2D6TSHRMTORADK | |
| SCHEMBL4582422 | 0.77 | TDP1 (0.54) | CYP2D6TSHRLMNABLMSMN1; SMN2 | |
| SCHEMBL8612344 | 0.76 | TAAR1 (0.53) | TAAR1CYP2D6TSHRMTORADK | |
| SCHEMBL19209978 | 0.75 | ALDH1A1 (0.43) | TAAR1MTORADKNISCHSMN1; SMN2 | |
| SCHEMBL5775644 | 0.71 | TAAR1 (0.41) | TAAR1CYP2D6TSHRMTORADK | |
| SCHEMBL20985591 | 0.71 | TAAR1 (0.41) | TAAR1CYP2D6TSHRMTORADK | |
| SCHEMBL5775648 | 0.71 | TAAR1 (0.41) | TAAR1CYP2D6TSHRMTORADK | |
| SCHEMBL5234870 | 0.71 | HTT (0.51) | TAAR1CYP2D6TSHRMTORADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170849-B1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-9187465-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-8921544-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2014-12-30 | — | — | US | disclosed |
| US-20140275041-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-8378095-B2 | Oxazole tyrosine kinase inhibitors | Saruem Limited (GB) | 2013-02-19 | — | — | US | disclosed |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2010055304-A2 | PHARMACEUTICAL COMPOUNDS | SAREUM LIMITED (GB) | 2010-05-20 | — | — | WO | disclosed |
| EP-2170849-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | Sareum Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008139161-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275041-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | TAAR1 992/4885CYP2D6 1612/4885TSHR 1522/4885 |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | TAAR1 992/4885CYP2D6 1612/4885TSHR 1522/4885 |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | TAAR1 992/4885CYP2D6 1612/4885TSHR 1522/4885 |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | TAAR1 947/4885CYP2D6 1702/4885TSHR 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.